511 related articles for article (PubMed ID: 31095430)
1. Pharmacological management of axial spondyloarthritis in adults.
Toussirot E
Expert Opin Pharmacother; 2019 Aug; 20(12):1483-1491. PubMed ID: 31095430
[No Abstract] [Full Text] [Related]
2. Advances in pharmacotherapies for axial spondyloarthritis.
Toussirot E
Expert Opin Pharmacother; 2023; 24(13):1439-1448. PubMed ID: 37318776
[TBL] [Abstract][Full Text] [Related]
3. Ankylosing Spondylitis versus Nonradiographic Axial Spondyloarthritis: Comparison of Tumor Necrosis Factor Inhibitor Effectiveness and Effect of HLA-B27 Status. An Observational Cohort Study from the Nationwide DANBIO Registry.
Glintborg B; Sørensen IJ; Østergaard M; Dreyer L; Mohamoud AA; Krogh NS; Hendricks O; Andersen LS; Raun JL; Kowalski MR; Danielsen L; Pelck R; Nordin H; Pedersen JK; Kraus DG; Christensen SR; Hansen IM; Esbesen J; Schlemmer A; Loft AG; Al Chaer N; Salomonsen L; Hetland ML
J Rheumatol; 2017 Jan; 44(1):59-69. PubMed ID: 27909080
[TBL] [Abstract][Full Text] [Related]
4. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis.
van der Heijde D; Ramiro S; Landewé R; Baraliakos X; Van den Bosch F; Sepriano A; Regel A; Ciurea A; Dagfinrud H; Dougados M; van Gaalen F; Géher P; van der Horst-Bruinsma I; Inman RD; Jongkees M; Kiltz U; Kvien TK; Machado PM; Marzo-Ortega H; Molto A; Navarro-Compàn V; Ozgocmen S; Pimentel-Santos FM; Reveille J; Rudwaleit M; Sieper J; Sampaio-Barros P; Wiek D; Braun J
Ann Rheum Dis; 2017 Jun; 76(6):978-991. PubMed ID: 28087505
[TBL] [Abstract][Full Text] [Related]
5. Management of Axial Spondyloarthritis - Insights into Upadacitinib.
Braun J; Kiltz U; Baraliakos X
Drug Des Devel Ther; 2022; 16():3609-3620. PubMed ID: 36268520
[TBL] [Abstract][Full Text] [Related]
6. Different drug survival of first line tumour necrosis factor inhibitors in radiographic and non-radiographic axial spondyloarthritis: a multicentre retrospective survey.
Lopalco G; Venerito V; Cantarini L; Emmi G; Salaffi F; Di Carlo M; Tafuri S; Gentileschi S; Di Scala G; Nivuori M; Cacciapaglia F; Galeazzi M; Lapadula G; Iannone F
Clin Exp Rheumatol; 2019; 37(5):762-767. PubMed ID: 31025925
[TBL] [Abstract][Full Text] [Related]
7. Certolizumab pegol for treating axial spondyloarthritis.
Desmarais J; Beier S; Deodhar A
Expert Opin Biol Ther; 2016 Aug; 16(8):1059-64. PubMed ID: 27366922
[TBL] [Abstract][Full Text] [Related]
8. Tumor necrosis factor α inhibition in radiographic and nonradiographic axial spondyloarthritis: results from a large observational cohort.
Ciurea A; Scherer A; Exer P; Bernhard J; Dudler J; Beyeler B; Kissling R; Stekhoven D; Rufibach K; Tamborrini G; Weiss B; Müller R; Nissen MJ; Michel BA; van der Heijde D; Dougados M; Boonen A; Weber U;
Arthritis Rheum; 2013 Dec; 65(12):3096-106. PubMed ID: 23983141
[TBL] [Abstract][Full Text] [Related]
9. New evidence on the management of spondyloarthritis.
Sieper J; Poddubnyy D
Nat Rev Rheumatol; 2016 May; 12(5):282-95. PubMed ID: 27052489
[TBL] [Abstract][Full Text] [Related]
10. Ixekizumab: an IL-17A inhibitor for the treatment of axial Spondylarthritis.
Harrison SR; Marzo-Ortega H
Expert Rev Clin Immunol; 2021 Oct; 17(10):1059-1071. PubMed ID: 34407705
[TBL] [Abstract][Full Text] [Related]
11. Have Therapeutics Enhanced Our Knowledge of Axial Spondyloarthritis?
Harrison SR; Marzo-Ortega H
Curr Rheumatol Rep; 2023 Mar; 25(3):56-67. PubMed ID: 36652160
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of biological DMARDs: a systematic literature review informing the 2022 update of the ASAS-EULAR recommendations for the management of axial spondyloarthritis.
Webers C; Ortolan A; Sepriano A; Falzon L; Baraliakos X; Landewé RBM; Ramiro S; van der Heijde D; Nikiphorou E
Ann Rheum Dis; 2023 Jan; 82(1):130-141. PubMed ID: 36270657
[TBL] [Abstract][Full Text] [Related]
13. Comparison of patients with ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA) from a single rheumatology clinic in New Delhi.
Malaviya AN; Kalyani A; Rawat R; Gogia SB
Int J Rheum Dis; 2015 Sep; 18(7):736-41. PubMed ID: 26172961
[TBL] [Abstract][Full Text] [Related]
14. American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis.
Ward MM; Deodhar A; Akl EA; Lui A; Ermann J; Gensler LS; Smith JA; Borenstein D; Hiratzka J; Weiss PF; Inman RD; Majithia V; Haroon N; Maksymowych WP; Joyce J; Clark BM; Colbert RA; Figgie MP; Hallegua DS; Prete PE; Rosenbaum JT; Stebulis JA; van den Bosch F; Yu DT; Miller AS; Reveille JD; Caplan L
Arthritis Rheumatol; 2016 Feb; 68(2):282-98. PubMed ID: 26401991
[TBL] [Abstract][Full Text] [Related]
15. Golimumab in radiographic and nonradiographic axial spondyloarthritis: a review of clinical trials.
Toussirot E; Vauchy C; Binda D; Michel F
Drug Des Devel Ther; 2016; 10():2087-94. PubMed ID: 27445459
[TBL] [Abstract][Full Text] [Related]
16. Current therapeutics for spondyloarthritis.
Toussirot É
Expert Opin Pharmacother; 2011 Nov; 12(16):2469-77. PubMed ID: 21988214
[TBL] [Abstract][Full Text] [Related]
17. Tumor Necrosis Factor-α Inhibition in Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis: Treatment Response, Drug Survival, and Patient Outcome.
Corli J; Flipo RM; Philippe P; Bera-Louville A; Béhal H; Wibaux C; Paccou J
J Rheumatol; 2015 Dec; 42(12):2376-82. PubMed ID: 26568593
[TBL] [Abstract][Full Text] [Related]
18. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update.
Ramiro S; Nikiphorou E; Sepriano A; Ortolan A; Webers C; Baraliakos X; Landewé RBM; Van den Bosch FE; Boteva B; Bremander A; Carron P; Ciurea A; van Gaalen FA; Géher P; Gensler L; Hermann J; de Hooge M; Husakova M; Kiltz U; López-Medina C; Machado PM; Marzo-Ortega H; Molto A; Navarro-Compán V; Nissen MJ; Pimentel-Santos FM; Poddubnyy D; Proft F; Rudwaleit M; Telkman M; Zhao SS; Ziade N; van der Heijde D
Ann Rheum Dis; 2023 Jan; 82(1):19-34. PubMed ID: 36270658
[TBL] [Abstract][Full Text] [Related]
19. New treatment options and emerging drugs for axial spondyloarthritis: biological and targeted synthetic agents.
Toussirot E
Expert Opin Pharmacother; 2017 Feb; 18(3):275-282. PubMed ID: 28099816
[TBL] [Abstract][Full Text] [Related]
20. Biologics for treating axial spondyloarthritis.
Jones A; Ciurtin C; Ismajli M; Leandro M; Sengupta R; Machado PM
Expert Opin Biol Ther; 2018 Jun; 18(6):641-652. PubMed ID: 29681195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
